AdaptHealth to appoint Harriss Currie CFO in 2026
AdaptHealth is replacing its CFO, granting the incoming executive significant cash and equity compensation with defined severance protections.
Rhea-AI Filing Summary
AdaptHealth Corp. (AHCO) announced a planned Chief Financial Officer transition, appointing Harriss Currie as CFO effective September 9, 2026, while current CFO Jason Clemens will cease serving as CFO on September 8, 2026 and remain through October 1, 2026 to assist with the transition.
Currie joins with extensive healthcare and diagnostics experience, including more than 15 years as CFO of Luminex Corp. His employment agreement provides an annual base salary of $670,000 and a target annual bonus equal to 100% of base salary, with a prorated 2026 bonus. As an inducement, he will receive RSUs valued at $818,462, half vesting annually over three years and half cliff-vesting on the third anniversary of his start date, subject to continued employment. Upon certain qualifying terminations, he is eligible for 12 months of base-salary severance, a prorated bonus (under stated conditions), and 12 months of COBRA health coverage, subject to a release and restrictive covenants.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
restricted stock units financial
cliff-vest financial
qualifying termination financial
non-compete covenant regulatory
non-solicit covenants regulatory
COBRA regulatory
FAQ
What executive leadership change did AdaptHealth (AHCO) announce?
What are the key compensation terms for the new AdaptHealth (AHCO) CFO?
How will Harriss Currie’s RSU award at AdaptHealth (AHCO) vest?
What severance protections does the new AdaptHealth (AHCO) CFO have?
What restrictive covenants apply to the new AdaptHealth (AHCO) CFO?
What will the outgoing CFO of AdaptHealth (AHCO) receive upon departure?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) | |
| ( |
||
(Registrant’s telephone number, including area code) |
||
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Chief Financial Officer Appointment
AdaptHealth Corp. (the “Company”) announced today that Harriss Currie, age 64, has been appointed to serve as the Chief Financial Officer of the Company, effective as of September 9, 2026 (the “Start Date”).
Mr. Currie served as Chief Financial Officer at Health Track RX, a developer of an infectious disease diagnostics platform, from December 2025 to May 2026. Previously, he served as President of the Regenerative Medicine Division of 3D Systems, a developer of high-resolution 3D bioprinting technologies, from December 2023 to July 2025. Before that, Mr. Currie served as Chief Financial Officer at Impulse Dynamics, a medical device company that develops treatments for chronic heart failure, from January 2022 to July 2023, and as Chief Financial Officer of Luminex Corp., a developer, manufacturer, and marketer of proprietary biological testing technologies and diagnostic tools for clinical laboratories and researchers, from October 2003 until its sale to DiaSorin in July 2021. Mr. Currie holds an MBA from the McCombs School of Business at the University of Texas at Austin and previously served as an audit manager at Deloitte & Touche.
There are no arrangements or understandings between Mr. Currie and any other person pursuant to which Mr. Currie was selected as an officer, and there are no family relationships between Mr. Currie and any of the Company’s directors or executive officers. Mr. Currie does not have any direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.
On September 7, 2026, the Company entered into an employment agreement with Mr. Currie (the “Currie Employment Agreement”) that will govern the terms of his employment as the Chief Financial Officer of the Company from and after the Start Date. Pursuant to the terms of the Currie Employment Agreement, Mr. Currie is entitled to receive an annual base salary of $670,000 and is eligible to receive a target annual incentive bonus equal to 100% of his base salary, with the actual bonus based on the achievement of annual performance objectives for such fiscal year. For the Company’s 2026 fiscal year, Mr. Currie will be paid a prorated target bonus subject to his continued employment through the payment date.
As an inducement for Mr. Currie to join the Company, the Company will grant Mr. Currie restricted stock units (“RSUs”) under the Company’s Second Amended and Restated 2019 Stock Incentive Plan covering a number of shares of the Company’s common stock with a value of $818,462 (determined in a manner consistent with the Company’s historic practices), 50% of which will vest in equal installments annually over three years and the remaining 50% will cliff-vest in a single installment on the third anniversary of the Start Date, in each case, subject to continued employment. Mr. Currie will also be eligible for additional equity awards commencing in 2027.
Pursuant to the Currie Employment Agreement, if Mr. Currie’s employment is terminated (x) by the Company without “cause” or (y) by Mr. Currie for “good reason” (as such terms are defined in the Currie Employment Agreement) (either such termination, a “qualifying termination”), subject to his execution and non-revocation of a general release of claims in favor of the Company and its affiliates and compliance with certain restrictive covenants (described below), Mr. Currie will be entitled to (i) any earned but unpaid annual bonus in respect of any completed fiscal year that has ended prior to the date of such termination, (ii) continued payment of base salary for a period of 12 months following such date of termination, (iii) if such qualifying termination occurs on or after April 1 of the applicable year of termination, a prorated annual bonus payable in respect of the calendar year of termination based on actual performance, and (iv) 12 months’ continuation of health insurance coverage pursuant to COBRA at the same rate which applies for active executive officers.
In connection with the Currie Employment Agreement, Mr. Currie also entered into a restrictive covenant agreement, which includes a non-compete covenant that applies during employment and for 12 months thereafter, non-solicit covenants that apply during employment and for 24 months thereafter, indefinite confidentiality and invention assignment covenants, and a non-disparagement covenant that applies during employment and for two years thereafter.
- 2 -
The foregoing description of the Currie Employment Agreement is qualified in its entirety by reference to the full text of the Currie Employment Agreement, which is attached as Exhibit 10.1 hereto and incorporated by reference herein.
Chief Financial Officer Departure
The Company announced today that Jason Clemens, the Company’s Chief Financial Officer, will terminate his employment with the Company effective as of October 1, 2026 (the “Separation Date”); provided, that Mr. Clemens’ appointment to the position and authority to act as the Company’s Chief Financial Officer will end as of the close of business on September 8, 2026.
Mr. Clemens will receive severance and other benefits available for a termination by the Company without “cause” (as defined in Mr. Clemens’ employment agreement, dated May 1, 2020, as amended on April 15, 2024 and December 9, 2024 (the “Clemens Employment Agreement”)), in accordance with the terms of the previously disclosed Clemens Employment Agreement.
Item 7.01 Regulation FD Disclosure
The Company issued a press release earlier today announcing the appointment of Mr. Currie as Chief Financial Officer, as described in Item 5.02 above. A copy of the press release is furnished as Exhibit 99.1.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
| d) | Exhibits |
| Exhibit No. | Description | |
| 10.1 | Employment Agreement by and between AdaptHealth Corp. and Harriss Currie, dated September 7, 2026. | |
| 99.1 | Press Release dated September 8, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
- 3 -
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: September 8, 2026
| AdaptHealth Corp. | |||
| By: | /s/ Richard Rew | ||
| Name: | Richard Rew | ||
| Title: | Chief Legal Officer and General Counsel | ||
- 4 -
Exhibit 99.1
ADAPTHEALTH CORP.
FOR IMMEDIATE RELEASE
AdaptHealth Appoints Harriss Currie as Chief Financial Officer
PLYMOUTH MEETING, Pa. – September 8th 2026 - AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that its Board of Directors has named Harriss T. Currie as its Chief Financial Officer, effective September 9, 2026. Mr. Currie will assume CFO responsibilities from Jason Clemens, who will assist with the transition through October 1, 2026.
Mr. Currie previously served as the CFO for Luminex Corp (Nasdaq: LMNX) for more than 15 years until its sale to DiaSorin in 2021. He has more recently held CFO roles at Health Track Rx from 2025 to 2026 and from Impulse Dynamics from 2022 to 2023, and served as President of the Regenerative Medicine division of 3D Systems (NYSE: DDD) from 2023 to 2025.
Mr. Currie holds an MBA from the McCombs School of Business at the University of Texas at Austin and previously served as an audit manager at Deloitte & Touche.
“We are delighted to welcome Harriss to AdaptHealth and look forward to the meaningful contributions we expect he will make in both the short and long term,” said Suzanne Foster, Chief Executive Officer. “We appreciate Jason’s years of service and are particularly thankful for the strong team and structure he has left for Harriss to build on.”
“I am excited to join AdaptHealth and to lead the finance team through our next phase of growth. In evaluating this opportunity, I saw a strong leadership team, solid financial processes, and a business that has put strategic contracts in place to position itself for meaningful revenue and EBITDA growth. I am truly excited and appreciative of this opportunity,” said Mr. Currie.
About AdaptHealth Corp.
AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including CPAP and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Diabetes Health segment provides medical devices, including continuous glucose monitors and insulin pumps, and related services to patients for the treatment of diabetes. The Wellness at Home segment provides home medical equipment and services to patients in their homes including those who have been discharged from acute care and other facilities. The segment tailors a service model to patients who are adjusting to new lifestyles or navigating complex disease states by providing essential medical supplies and durable medical equipment.
- 1 -
ADAPTHEALTH CORP.
The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid, and commercial insurance payors, reaching approximately 4.5 million patients annually in all 50 states through its network of approximately 670 locations in 48 states.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations and the Company’s acquisition pipeline. These statements are based on various assumptions and on the current expectations of AdaptHealth management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company.
These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which the Company may become a party or governmental investigations to which the Company may become subject that could interrupt or limit the Company’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in the Company’s customers’ preferences, prospects and the competitive conditions prevailing in the healthcare sector. A further description of such risks and uncertainties can be found in the Company’s filings with the Securities and Exchange Commission. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently knows or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts
Luke Montgomery, CFA
SVP, Investor Relations
luke.montgomery@adapthealth.com
IR@adapthealth.com
- 2 -